The global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 16.0 Billion by 2028, exhibiting a growth rate (CAGR) of 4.6% during 2023-2028.
Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient’s cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.
Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient’s cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.
Antihyperlipidemic Drugs Market Trends:
The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global antihyperlipidemic drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, route of administration and distribution channel.Breakup by Drug Class:
- Statins
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- PCSK9 Inhibitors
- Combination
- Others
Breakup by Route of Administration:
- Oral
- Intravenous
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Stores
- Online Retailers
Breakup by Region:
North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.Key Questions Answered in This Report:
- What was the size of the global antihyperlipidemic drugs market in 2022?
- What is the expected growth rate of the global antihyperlipidemic drugs market during 2023-2028?
- What are the key factors driving the global antihyperlipidemic drugs market?
- What has been the impact of COVID-19 on the global antihyperlipidemic drugs market?
- What is the breakup of the global antihyperlipidemic drugs market based on the drug class?
- What is the breakup of the global antihyperlipidemic drugs market based on the distribution channel?
- What are the key regions in the global antihyperlipidemic drugs market?
- Who are the key players/companies in the global antihyperlipidemic drugs market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Antihyperlipidemic Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Route of Administration
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Amgen Inc.
- AstraZeneca plc
- Daiichi Sankyo Company Limited
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc. and Sanofi S.A.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 144 |
Published | May 2023 |
Forecast Period | 2022 - 2028 |
Estimated Market Value ( USD | $ 12 Billion |
Forecasted Market Value ( USD | $ 16 Billion |
Compound Annual Growth Rate | 4.9% |
Regions Covered | Global |
No. of Companies Mentioned | 6 |